BRUSSELS—U.S. officials conduct hundreds of inspections of pharmaceutical plants in the European Union each year, duplicating inspections performed by EU authorities. European inspectors do the same in the U.S.. It is a swath of red tape that the drug industry and European regulators hoped would be eliminated as part of negotiations on a sweeping trade and investment deal between the U.S. and the EU. But the U.S. is reluctant to stop its inspections in the EU, fearing that audits done by poorer countries in the 28-nation bloc...
  